Document is current

Any future updates will be listed below

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

Crossref DOI link: https://doi.org/10.1007/s00415-015-7834-0

Published Online: 2015-09-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark